Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition

Pfizer Inc.

today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer's pending acquisition of Hospira

. The FTC's clearance is contingent upon Pfizer's commitment to divest four U.S. sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan. In addition, Pfizer announced that Brazil's Superintendency-General of CADE has published its unconditional clearance decision. "We are pleased to have received these final regulatory approvals for our pending acquisition of Hospira," said Ian Read, Chairman and Chief Executive Officer, Pfizer. "We now look forward to combining our two companies and expect the transaction to close in early September." About Pfizer: